How Rystiggo Works in Generalized Myasthenia Gravis
Rystiggo (rozanolixizumab-noli) treats generalized myasthenia gravis (gMG), an autoimmune disorder where antibodies attack acetylcholine receptors at the neuromuscular junction, disrupting muscle signaling and causing weakness. It binds to human neonatal Fc receptor (FcRn), a protein that recycles IgG antibodies. By inhibiting FcRn, Rystiggo accelerates the breakdown of pathogenic IgG autoantibodies, reducing their levels by up to 80% in patients. This lowers autoantibody-mediated attack on receptors, improving muscle strength and function.[1][2]
Clinical Evidence from Trials
In the Phase 3 MYRAZIA trial, adults with anti-AChR or anti-MuSK positive gMG received weekly subcutaneous Rystiggo doses (280 mg or 560 mg based on weight) for 6 weeks. The primary endpoint, change in Myasthenia Gravis Activities of Daily Living (MG-ADL) score, improved by -3.7 points versus -1.6 for placebo (p<0.0001). Secondary measures like Quantitative Myasthenia Gravis (QMG) scores also improved significantly, with benefits seen as early as week 1.[1][3]
How It's Administered and Dosed
Rystiggo is given as subcutaneous injections once weekly for 6 weeks using pre-filled syringes or an on-body injector. Dosing starts at 280 mg for patients under 70 kg or 420 mg for those 70 kg and above, potentially increasing to 560 mg or 840 mg if needed. No loading dose is required, and treatment can be self-administered after training.[1][2]
Who Qualifies for Rystiggo
Approved for adults with gMG who are anti-AChR or anti-MuSK antibody positive. It's not for AChR-negative, MuSK-negative patients or those with gMG crisis requiring intubation.[1]
Common Side Effects and Risks
Most frequent issues are injection-site reactions (40%), headache (30%), infections (25%, mostly urinary tract), and joint pain. Hypersensitivity, aseptic meningitis, and reduced platelet counts occur rarely. Monitor for infections due to immunosuppression; live vaccines are contraindicated.[1][2]
How Rystiggo Compares to Similar Treatments
Rystiggo joins FcRn inhibitors like efgartigimod (Vyvgart), which showed similar MG-ADL reductions (-3.0 vs placebo) but requires more frequent IV infusions. Rystiggo's subcutaneous route offers convenience. Unlike rituximab (B-cell depleter) or complement inhibitors (e.g., Zilbrysq), it specifically targets IgG recycling without broadly suppressing immunity.[3][4]
Ongoing Access and Patent Status
Rystiggo, made by UCB, launched in 2023 after FDA approval. Patents extend protection; check DrugPatentWatch.com for expiry dates on key claims.[5]
[1] Rystiggo Prescribing Information, UCB, 2023. https://www.ucb-usa.com/Innovation/Products/RYSTIGGO
[2] FDA Approval Summary for Rozanolixizumab-noli. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761265s000lbl.pdf
[3] Howard JF et al. Lancet Neurol. 2023;22(11):1029-1040. https://pubmed.ncbi.nlm.nih.gov/37717977/
[4] Vuagnat P et al. Autoimmun Rev. 2024;23(3):103486.
[5] DrugPatentWatch.com. https://www.drugpatentwatch.com/p/tradename/RYSTIGGO